まとめ
経口ラテリルは,シアン酸の放出により,ハムスターの子犬の骨格不形成を引き起こしました. 静脈内投与のラエトリルはこれらの効果を引き起こさなかったし,チオスルファートは経口ラエトリルの毒性から保護された.
科学分野:
- 毒理学 毒理学 毒理学
- 発達生物学 発達生物学とは
- 薬理学 薬理学とは
背景:
- ラエトリル (Laetrile) は,杏仁の核に含まれる化合物で,潜在的な健康上の利点について調査されています.
- ラエトリルの安全性,特に妊娠中の安全性について懸念があります.
- ラエトリルの代謝の運命とテロジェニックの可能性については,さらなる解明が必要である.
研究 の 目的:
- 妊娠しているハムスターに口服および静脈注射されたラエトリルのテロゲン効果を調査する.
- ラエトリル誘発胚病におけるシアン酸の役割を決定する.
- ラエトリル毒性に対するチオスルファートの保護効果を評価する.
主な方法:
- 妊娠しているハムスターは,ラエトリルを経口または静脈内投与した.
- 子孫の骨格の発達は,不形成の有無を検査した.
- シアン化物インシット濃度は,母体および胚組織で測定されました.
- 硫酸チオスルファートは,その保護的役割を評価するために投与されました.
主要な成果:
- 経口ラエトリル投与は,子孫における重要な骨格不形成を引き起こした.
- 静脈内レトリル投与は胚病的な効果を生じませんでした.
- 口服用ラエトリルは,in situシアン化物濃度を有意に増加させた.
- チオスルファートの投与は,胚を口服用ラエトリルのテラトジェニック作用から保護した.
結論:
- 経口用ラエトリルのテロジェニック効果は,細菌のβ-グルコシダース活性によって放出されたシアン酸によって媒介される可能性が高い.
- 静脈内投与は,この代謝経路を回避し,テロゲニシティを回避します.
- これらの発見は,ラエトリルの毒性における代謝活性化の重要性を強調し,そのテロゲン性可能性のメカニズムを示唆しています.
さらに関連する動画
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
関連する概念動画
Mutations
Overview
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
